

Vasily Shuvaev

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8873632/publications.pdf>

Version: 2024-02-01

21
papers

185
citations

1478458

6
h-index

1125717

13
g-index

23
all docs

23
docs citations

23
times ranked

336
citing authors

#	ARTICLE	IF	CITATIONS
1	Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase. <i>Annals of Internal Medicine</i> , 2018, 168, 461.	3.9	105
2	Treatment-Free Remission in Patients with Chronic Myeloid Leukemia in Chronic Phase According to Reasons for Switching from Imatinib to Nilotinib: Subgroup Analysis from ENESTop. <i>Blood</i> , 2016, 128, 792-792.	1.4	16
3	Phase-1 Study of PF-114 Mesylate in CML Failing Prior Tyrosine Kinase-Inhibitor Therapy. <i>Blood</i> , 2018, 132, 790-790.	1.4	13
4	Efficacy of Tyrosine Kinase Inhibitors in Third Line Therapy in Chronic Phase Chronic Myeloid Leukemia. <i>Blood</i> , 2015, 126, 4051-4051.	1.4	11
5	Patient-Reported Quality of Life before and after Stopping Treatment in the ENESTop Trial of Treatment-Free Remission for Patients with Chronic Myeloid Leukemia in Chronic Phase. <i>Blood</i> , 2016, 128, 1891-1891.	1.4	9
6	Treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with second-line nilotinib (NIL): First results from the ENESTop study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 7054-7054.	1.6	6
7	The combination treatment regimen of ruxolitinib with low-dose mercaptopurine or cytarabine in frail patients with blast-phase myelofibrosis. <i>British Journal of Haematology</i> , 2017, 178, 645-646.	2.5	4
8	Long-term treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after stopping second-line (2L) nilotinib: ENESTop 144-wk results.. <i>Journal of Clinical Oncology</i> , 2018, 36, 7003-7003.	1.6	4
9	ENESTop 144-Week Update: Long-Term Treatment-Free Remission (TFR) in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After Stopping Second-Line Nilotinib. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S222.	0.4	3
10	National clinical recommendations for the diagnosis and treatment of mastocytosis. <i>Gematologiya i Transfuziologiya</i> , 2021, 66, 280-311.	0.6	3
11	Pharmacoeconomical Analysis of Chronic Myelogenous Leukemia Treatment Free Remission. <i>Blood</i> , 2015, 126, 3293-3293.	1.4	3
12	Atypical Chronic Myeloid Leukemia Challenge in Russian Hematology Practice. <i>Blood</i> , 2018, 132, 5483-5483.	1.4	1
13	Genetic and Epigenetic Alterations of Ph-Negative Myeloproliferative Neoplasms. <i>Blood</i> , 2014, 124, 5549-5549.	1.4	0
14	Frequent Mutations and Their Influence on Prognosis in Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 4949-4949.	1.4	0
15	The Influence of Hemostasis Genetic Features on Thrombosis Rates in Patients with Polycythemia Vera. <i>Blood</i> , 2015, 126, 5180-5180.	1.4	0
16	THROMBOTIC AND BLEEDING RISK FACTORS IN ESSENTIAL THROMBOCYTHEMIA. <i>Oncogematologiya</i> , 2017, 12, 30-38.	0.3	0
17	Russian Experience of Bosutinib Use in Chronic Myeloid Leukemia Patients in Routine Clinical Practice. <i>Blood</i> , 2018, 132, 5446-5446.	1.4	0
18	The Prognostic Significance of Minimal Residual Disease and Possibility of Its Correction in Multiple Myeloma. <i>Blood</i> , 2018, 132, 5751-5751.	1.4	0

#	ARTICLE	IF	CITATIONS
19	Influence of Minimal Residual Disease on Survival of Patients with Mantle Cell Lymphoma. Blood, 2018, 132, 1611-1611.	1.4	0
20	Peculiarities of plasma hemostasis in patients with Ph-negative myeloproliferative neoplasms. Tromboz, Gemostaz I Reologiya, 2020, , .	0.2	0
21	The use of non-cryopreserved hematopoietic stem cells for autologous transplantation in multiple myeloma patients. Oncogematologiya, 2022, 17, 82-94.	0.3	0